정신과에서 분자유전학의 치료적 적용

이민수,Lee, Min Soo 대한생물정신의학회 1998 생물정신의학 Vol.5 No.1

Advances in molecular biology contribute to the understanding genetic mechanism of psychiatric disorders. They have renewed hope for the discovery of disease relevant gene. However, the results somewhat confused. And we will wait for a long time for the application of gene therapy in schizophreniar. Fortunately we could classified the schizophrenia with genotypes of dopamine and serotonin receptors. It is expected that this genetic classification could provide key strategy for the therapeutic application in biological treatment for schizophrenia. The purpose of this article is to call attention of the institute participants to linkage, association, mRNA expression, genotypic classification and to the need for more systemic research. The author summarized the modified methods which were done in his laboratory in appendix.

만성 정신분열증환자에 대한 Sertraline병합치료 효과

이민수,김용구,이상규,서광윤,Lee, Min-Soo,Kim, Yong-Ku,Lee, Sang-Kyu,Suh, Kwang-Yoon 대한생물정신의학회 1997 생물정신의학 Vol.4 No.1

Objective : To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. Method : Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6, and 8 weeks of treatment. Results : The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI, and S-A scale scores at any between sertaline and placebo treatment. Conclusion : This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.

우세안과 비우세안의 망막신경섬유층 두께, 시신경유두 형태 비교

이민수,조경진,조우형,경성은,장무환.Min Soo Lee. MD. Kyong Jin Cho. MD. Woo Hyung Cho. MD. Sung Eun Kyung. MD. PhD.Moo Hwan Chang. MD. PhD 대한안과학회 2013 대한안과학회지 Vol.54 No.5

Purpose: To investigate the comparison of retinal nerve fiber layer (RNFL) thickness and optic disc parameters measured by optical coherence tomography (Cirrus HD-OCT<sup>®) in dominant and non-dominant eyes. Methods: Seventy-one subjects without underlying ocular disease were recruited for the present study. Ocular dominance was determined using the hole-in-the-card test. Comprehensive standardized eye examinations were performed. Scans of the optic disc and RNFL were performed using OCT. Results: The mean intraocular pressure (IOP) of the dominant eye was higher than its counterpart (p = 0.025). No significant differences were observed in uncorrected visual acuity, refractive error and axial length between dominant and non-dominant eyes (p = 0.235, 0.180, 0.850). No RNFL and optic disc features were identified in the dominant from non-dominant eyes. Conclusions: Although dominant eyes tended to have higher IOP than non-dominant eyes, no consistent ocular structural differences between dominant and non-dominant eyes with the use of OCT were found.

Tofisopam과 lorazepam의 항불안효과와 안전성에 대한 비교 연구

이민수,김용구,곽동일,Lee, Min Soo,Kim, Yong-Ku,Kwak, Dong-Il 대한생물정신의학회 1997 생물정신의학 Vol.4 No.2

2,3-benzodiazepine계 항불안제인 tofisopam의 항불안 효과 및 안전성을 조사하기 위해 단일맹검 비교연구를 시행하였다. 외래로 내원한 불안 장애 환자 40명을 대상으로 무작위로 tofisopam군과 lorazepam군으로 할당하였으며, 최종 연구를 완결한 환자는 tofisopam군 17명(남자 7명, 여자 10명), lorazepam군은 15명(남자 6명, 여자 9명)이었다. 초기용량으로 tofisopam군은 50mg을 하루 3회 복용하고, lorazepam군은 0.75mg을 하루 2회 복용하도록 하였으며, 임상상태와 부작용에 따라 용량을 임의로 증감하도록 하였고, 일일 최대 용량은 tofisopam군 300mg, lorazepam군 3mg으로 하였다. 임상상태에 대한 평가는 Hamilton rating scale for anxiety(HAM-A)와 Clinical global impression(CGI)으로 하였으며, 약물 투여전과 투여 1주후, 2주후, 4주후에 측정되었다. 결과는 다음과 같다. 1) HAM-A 총점수의 경우, 약물 치료군과 시점을 변인으로 한 two-way repeated-measure ANOVA에서 양군간에 시점에 따른 유의한 차이는 없었다. HAM-A 심리적 불안과 신체적 불안아척도 점수에서 양군간 시점에 따른 유의한 차이는 없었다. 각 군에서 HAM-A 총점수의 시점에 따른 유의한 변화를 나타내었으며, 양군 모두 1주후부터 유의한 감소를 나타내었다. 2) CGI의 질병의 전반적인 심각도에서 약물 치료군과 시점을 변인으로 한 two-way repeated-measure ANOVA에서 양군간에 시점에 따른 유의한 차이는 없었다. 각 군에서 CGI 심각도의 시점에 따른 유의한 변화를 나타내었으며, tofisopam군은 1주후부터 lorazepam군은 4주후부터 유의한 감소를 나타내었다. CGI 호전도에선 각 시점에서"minimally improved"이상을 보인 환자군이 tofisopam군이 94.1%로서 lorazepam군 66.7% 보다 높았다. 3) 안전성 분석에서 각 군에서 생명징후, 혈액학, 생화학, 심전도, 체중에서 유의한 변화를 보이지 않았다. 4) 부작용 면에서 tofisopam군이 lorazepam군보다 각 시점에서 부작용을 호소한 환자수가 적었다. 이상에서 tofisopam은 lorazepam과 유사한 항불안효과를 보였으며, 내약성은 lorazepam에 비해 우수하였다. Objective : A 4-week, single-blind, parallel group study was conducted to evaluate the efficacy and safety of tofisopam and lorazepam in 32 outpatients with anxiety disorder. Methods : Patients were randomized to receive either tofisopam(N=17) or lorazepam(N=15). The starting dose of tofisopam was 50mg t.i.d. daily, which could be increased to a maximum of 100mg t.i.d. according to the patient's clinical response and side effect. The starting dose of lorazepam was 0.75mg b.i.d. daily, which could be increased to a maximum of 1.5mg b.i.d. depending on the patient's clinical response and side effect. Efficacy evaluations at baseline, week 1, 2, and 4 used the 14-item Hamilton Rating Scale for Anxiety(HAM-A) and Clinical Global Impression(CGI). Tolerability was assessed by response to a nonleading question concerning adverse events. Laboratory parameters including vital sign, EKG, hematological, and biochemical values were measured during trial. Results : No significant differences between HAM-A total scores, two HAM-A factors(psychic, somatic) and CGI severity scores were recorded at any point during tofisopam and lorazepam treatments. However, in each group there was a significant decrease in HAM-A total scores, two HAM-A factor s(psychic, somatic), CGI severity scores over time. The pecentages of patients with tofisopam who at least minimally improved increased from 64.7% at week 1 to 94.1% at week 4. The pecentages of patients with lorazepam who at least minimally improved increased from 40.0% at week 1 to 66.7% at week 4. The pecentages of patients with tofisopam who had not any adverse event increased from 58.8% at week 1 to 87.9% at week 4. The pecentages of patients with lorazepam who had not any adverse event were not changed from 46.7% at week 1 to 46.7% at week 4. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial in both groups. Conclusion : These data suggest that tofisopam may be effective in reducing anxiety and is a anti-anxiety drug of identical potency with lorazepam. Tolerability of tofisopam was superior to lorazepam. These findings should be confirmed by using double-blind crossover study with a large member of patients.

폐렴사슬알균 수막염 환자에서 발생한 양안 내인성 안내염 1예

이민수,장무환,Min Soo Lee,Moo Hwan Chang 대한안과학회 2013 대한안과학회지 Vol.54 No.2

Purpose: To report a case of bilateral endogenous endophthalmitis in a Streptococcus pneumoniae meningitis patient. Case summary: A 45-year-old woman with bacterial meningitis was referred to the ophthalmologic clinic with acute visual impairment in both eyes. The patient`s visual acuities were hand motion in both eyes. Ophthalmoscopy revealed inflammation in the anterior chamber and vitreous opacities in both eyes. Streptococcus pneumoniae was isolated in the cerebrospinal fluid sample, but not in vitreal, blood samples. Vision improved to 70/100 in the right eye and 2/100 in the left eye after 8 days of treatment. Conclusions: Endogenous endophthalmitis constitutes a rare complication of Streptococcus pneumoniae meningitis, and a prompt diagnosis and administration of empirical intravitreal antibiotics can lead to a more favorable visual prognosis.

항우울제와 연관약물의 약물상호작용

이민수,Lee, Min Soo 대한생물정신의학회 2000 생물정신의학 Vol.7 No.1

As the clinical practice of using more than one drug at a time increase, the clinician is faced with ever-increasing number of potential drug interactions. Although many interactions have little clinical significances, some may interfere with treatment or even be life-threatening. This review provides a better understanding of drug-drug interactions often encountered in pharmacotherapy of depression. Drug interactions can be grouped into two principal subdivisions : pharmacokinetic and pharmacodynamic. These subgroups serve to focus attention on possible sites of interaction as a drug moves from the site of administration and absorption to its site of action. Pharmacokinetic processes are those that include transport to and from the receptor site and consist of absorption, distribution on body tissue, plasma protein binding, metabolism, and excretion. Pharmacodynamic interactions occur at biologically active sites. In this review, emphasis is placed on antidepressant medications, how they are metabolized by the P450 system, and how they alter the metabolism of other drugs. When prescribing antidepressant medications, the clinician must consider the drug-drug interactions that are potentially problematic.

DNA Chip 데이터의 군집화 성능 향상을 위한 Particle Swarm Optimization 알고리즘의 적용기법

이민수,Lee, Min-Soo 한국정보처리학회 2010 정보처리학회논문지D Vol.17 No.3

최근 DNA 칩의 등장으로 유전자 관련 실험과 연구가 매우 용이해졌으며 이를 활용한 다양한 실험 결과로 대량의 데이터가 제공되고 있다. DNA칩에 의해 제공된 데이터는 2차원 행렬로 표현되며 하나의 축은 유전자를 나타내고 다른 하나의 축은 샘플정보를 나타낸다. 이러한 데이터에 대하여 빠른 시간 안에 좋은 품질의 군집화를 수행함으로써 이후의 분석 단계인 분류화 작업의 정확도와 효율성을 높일 수 있다. 본 논문에서는 생태계 모방 알고리즘의 하나인 Particle Swarm Optimization 알고리즘을 사용하여 방대한 양의 DNA칩 데이터에 대한 효율적인 군집화 기법을 제안하였으며 실험을 통해서 PSO 기반의 군집화 알고리즘이 기존의 군집화 알고리즘들보다 수행속도 및 품질 면에서 우수한 성능을 가짐을 보였다. Experiments and research on genes have become very convenient by using DNA chips, which provide large amounts of data from various experiments. The data provided by the DNA chips could be represented as a two dimensional matrix, in which one axis represents genes and the other represents samples. By performing an efficient and good quality clustering on such data, the classification work which follows could be more efficient and accurate. In this paper, we use a bio-inspired algorithm called the Particle Swarm Optimization algorithm to propose an efficient clustering mechanism for large amounts of DNA chip data, and show through experimental results that the clustering technique using the PSO algorithm provides a faster yet good quality result compared with other existing clustering solutions.

세로토닌 수송체와 기분장애

이민수,Lee, Min Soo 대한생물정신의학회 2001 생물정신의학 Vol.8 No.2

As numbers of serotonin's function are so many, studies of serotonin are numerous nowadays. In the beginning, concentration of metabolites such as 5-HIAA was a key issue, but recent studies have been challenged for serotonin receptor genes and their relation to mood disoder. Serotonin transporter(5-HTT) gene is a strong candidate gene of mood disoder for following reason. Serotonin transporter is a key protein in the serotonin pathway as it regulate the concentration of serotonin in the synaptic clept and essential pathophysiology of depression is dysregulation of 5-HTT so that all antidepressants have effect of 5-HTT antagonist. The decrease of 5-HTT in the platelet and in brain of the depressive patients is much consistent results in the studies of the pathophysiology of mood disorder till now. By this, we will be able to develop simple and easy marker for diagnosis, type, and treatment monitoring of depression. Many psychiatrists have sought the independent genes in relation to depression or schizophrenia. Obviously, the hereditary vulnerability contributes to etiology of mood disorders, but it is difficult to discriminate the independent genes because of many environmental factors. Moreover, in the hereditarily complex diseases such as mood disorder, the only vulnerability of gene can not sufficiently explain the etiology. In the future, to exclude the role of the gene-environmental interaction, the methods such as gene transfer can be considered. In the opposite direction, by using the gene destruction method, the role of target genes can be examined. As yet the concept of the gene expression, neural plasticity, neurogenesis and etc, is the elementary stage. The development of this field will help to establish the treatment strategy of chronic and refractory mood disorders.

SSRIs 이후의 항우울제

이민수,남종원,Lee, Min Soo,Nam, Jong Won 대한생물정신의학회 1999 생물정신의학 Vol.6 No.1

New antidepressants have become available for clinical use in the 1990s. Before this decade, the drugs available to treat depression consisted essentially of monoamine oxidase inhibitors, tricyclic antidepressants, and lithium. Following the introduction of SSRIs, the options have expanded and now include SSRIs, nefazodone, venlafaxine, mirtazapine, reboxetine, tianeptine. Newer antidepressants possess a variety of pharmacological characteristics that are relevant to the choice of an antidepressant for clinical use. This review summarizes some of the major pharmacological characteristics among the drugs.

특징 추출과 분석 기법에 기반한 단백질 상호작용 데이터 신뢰도 향상 시스템

이민수,박승수,이상호,용환승,강성희,Lee, Min-Su,Park, Seung-Soo,Lee, Sang-Ho,Yong, Hwan-Seung,Kang, Sung-Hee 한국정보처리학회 2006 정보처리학회논문지B Vol.13 No.7

대용량 실험으로부터 산출된 단백질 상호작용 데이터는 위양성(false positive) 데이터의 비율이 높다는 단점을 가지고 있다. 본 논문에서는 오류가 섞여있는 단백질 상호작용 데이터를 입력으로 받아 각 단백질 상호작용의 신뢰도를 검증하는 시스템을 제안하고 구현하였다. 제안 시스템은 단백질 상호작용 데이터에 상호작용의 근거로서 사용될 수 있는 다양한 생물학적 특징들에 관한 데이터를 통합하고 특징 선택 방법을 사용하여 통합된 속성들 중 위양성 여부를 판별하는데 가장 적합한 특징들을 선택한 후 데이터 마이닝 분류 알고리즘을 적용하여 대용량 실험으로부터 산출된 단백질 상호작용 데이터의 신뢰도를 평가한다. 특징 선택의 결과와 분류 기법의 성능은 데이터 특성에 매우 의존하므로, 제안시스템에 가장 적합한 속성 부분집합과 가장 좋은 성능을 내는 분류 알고리즘을 찾기 위해 다양한 특징 선택 방법과 데이터 마이닝 분류 알고리즘들을 적용하고 그 성능을 다각적으로 비교분석 하였다. 실험 결과, 특징 선택 방법과 분류 알고리즘을 결합시킨 제안 시스템은 오류 데이터가 섞여있는 단백질 상호작용 데이터에서 실제로 상호작용하는 단백질 쌍을 골라내는 작업에 있어 기존 연구들에 비해 매우 뛰어난 성능을 보여줬다. 또한 본 연구를 통해 단백질 상호작용 데이터의 신뢰도를 검증함에 있어서 다양한 특징 선택 방법들과 분류 알고리즘들이 성능에 미치는 영향에 관해서도 정리할 수 있었다. Protein-protein interaction data obtained from high-throughput experiments includes high false positives. In this paper, we introduce a new protein-protein interaction reliability verification system. The proposed system integrates various biological features related with protein-protein interactions, and then selects the most relevant and informative features among them using a feature selection method. To assess the reliability of each protein-protein interaction data, the system construct a classifier that can distinguish true interacting protein pairs from noisy protein-protein interaction data based on the selected biological evidences using a classification technique. Since the performance of feature selection methods and classification techniques depends heavily upon characteristics of data, we performed rigorous comparative analysis of various feature selection methods and classification techniques to obtain optimal performance of our system. Experimental results show that the combination of feature selection method and classification algorithms provide very powerful tools in distinguishing true interacting protein pairs from noisy protein-protein interaction dataset. Also, we investigated the effects on performances of feature selection methods and classification techniques in the proposed protein interaction verification system.